Sigma Planning Corp Buys 4,416 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sigma Planning Corp lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,476 shares of the biopharmaceutical company’s stock after buying an additional 4,416 shares during the quarter. Sigma Planning Corp’s holdings in Gilead Sciences were worth $2,650,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of GILD. Albion Financial Group UT acquired a new position in Gilead Sciences during the second quarter worth approximately $27,000. Sawyer & Company Inc bought a new position in shares of Gilead Sciences during the 2nd quarter worth approximately $28,000. Meridian Wealth Partners LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth approximately $32,000. Elmwood Wealth Management Inc. bought a new stake in Gilead Sciences in the 1st quarter valued at $35,000. Finally, Samalin Investment Counsel LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at $58,000. Institutional investors and hedge funds own 78.04% of the company’s stock.

GILD has been the topic of several research analyst reports. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating and set a $72.00 price objective on the stock in a research report on Tuesday, August 10th. Royal Bank of Canada reissued a “buy” rating and issued a C$84.00 price target on shares of Gilead Sciences in a report on Monday, August 23rd. SVB Leerink boosted their price objective on Gilead Sciences from $74.00 to $77.00 and gave the stock an “outperform” rating in a report on Friday, July 30th. Morgan Stanley increased their target price on Gilead Sciences from $83.00 to $84.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, BMO Capital Markets boosted their price target on Gilead Sciences from $67.00 to $72.00 and gave the company a “market perform” rating in a research note on Friday, July 30th. Eight investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $105.72.

Shares of Gilead Sciences stock opened at $67.63 on Thursday. The company has a quick ratio of 1.19, a current ratio of 1.36 and a debt-to-equity ratio of 1.42. Gilead Sciences, Inc. has a 12-month low of $56.56 and a 12-month high of $73.34. The company has a market capitalization of $84.80 billion, a price-to-earnings ratio of 16.50, a PEG ratio of 0.63 and a beta of 0.39. The firm’s 50-day moving average price is $70.59 and its two-hundred day moving average price is $68.42.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, July 29th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.76 by $0.11. Gilead Sciences had a return on equity of 55.94% and a net margin of 19.38%. The firm had revenue of $6.22 billion during the quarter, compared to analysts’ expectations of $6.15 billion. During the same period in the prior year, the company earned $1.11 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.15 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 29th. Stockholders of record on Wednesday, September 15th were paid a $0.71 dividend. The ex-dividend date of this dividend was Tuesday, September 14th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.20%. Gilead Sciences’s payout ratio is currently 40.06%.

In related news, CAO Diane E. Wilfong sold 13,610 shares of the company’s stock in a transaction that occurred on Tuesday, August 17th. The shares were sold at an average price of $72.50, for a total transaction of $986,725.00. Following the completion of the transaction, the chief accounting officer now directly owns 30,179 shares in the company, valued at approximately $2,187,977.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.12% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Story: Example of operating income, EBIT and EBITDA

Want to see what other hedge funds are holding GILD? Visit to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with's FREE daily email newsletter.